DDInter1905 DDInter336
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ticagrelor {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Celecoxib
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ticagrelor {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketoprofen
Ketoprofen {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Celecoxib
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketoprofen
Ketoprofen {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Celecoxib
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lisinopril
Lisinopril {u} (Compound) treats {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is palliated by {v} (Compound) Celecoxib
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) ZMIZ1
ZMIZ1 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Celecoxib (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Celecoxib (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Celecoxib (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Celecoxib (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) treats systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Celecoxib (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Celecoxib (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Celecoxib (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates ZMIZ1 (Gene) and ZMIZ1 (Gene) is downregulated by Celecoxib (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Celecoxib (Compound)